TreatSMA

Petition to Fund Spinraza for all SMA patients needs 10,000 signatures!

Dear Community,

Earlier today we were contacted by Labour MP Kerry McCarthy on behalf of her constituent and SMA community member Jake Ogborne.

Jake and his family have started the petition ‘Fund Spinraza for all SMA patients on the NHS’. As many of you know, non-ambulant type 3 patients fall outside of the current MAA criteria to receive Spinraza. This means that Jake, and many others, are excluded from receiving this life saving/changing treatment.

We would love to get Jake’s petition to 10,000 signatures so that the government must give a written response. If you have not yet signed, please do so here.

Many thanks,

TreatSMA Team.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more